CTLA4 and neoplasm: Such a therapeutic strategy may combine ICBs directed to PD-1 or CTLA-4—which will reduce immune suppression—alongside with ICBs directed to PD-L1, enabling the latter to have better efficacy in preventing tumor progression, by targeting in full power the intrinsic metastasis-promoting functions of PD-L1.